EUVIMEDEUVIMED entdecken
Crossref

Genotype‐driven asthma prescribing of inhaled corticosteroids and long‐acting β2‐agonist: A cost‐effectiveness analysis

Jefferson Antonio Buendía iD, Andrés Felipe Zuluaga Salazar iD

Pediatric Pulmonology · 2024

DOI: 10.1002/ppul.27037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2024. Verfasst von Jefferson Antonio Buendía und 1 weiteren Autor:innen. Beteiligte Einrichtung: Research Group in Pharmacology and Toxicology, Department of Pharmacology and Toxicology, University of Antioquia, Medellín, Colombia. Hauptthemen laut MEDLINE: Asthma, Cost-Benefit Analysis, Receptors, Adrenergic, beta-2, Adrenergic beta-2 Receptor Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: This study was supported by the funding of authors.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Predicting response to inhaled corticosteroids (ICSs) + long‐acting β2‐agonist (LABA) by previously detecting the presence of Arg16Gly ADRB2 genotype is a strategy that could reduce and optimize the management of asthmatic patients. There is a need for economic evaluations to facilitate the implementation of such tests. This research aims to evaluate the cost‐effectiveness of Arg16Gly ADRB2 screening in children with asthma in Colombia.

Methods

From the perspective of a third‐party payer, we conducted a cost‐effectiveness analysis to determine the cost and quality‐adjusted life‐years (QALYs) of genotype‐driven asthma prescribing based on the Arg16Gly ADRB2 genotype versus current treatment based on no genetic testing. Using four state‐transition models, we estimate cost and QALYs employing micro‐simulation modeling with a time horizon of 10 years and a cycle length of 1 week. Cost‐effectiveness was assessed at a willingness‐to‐pay (WTP) value of US$5180.

Results

The mean incremental cost of strategy genetic testing versus no genetic testing is US$ −6809. The mean incremental benefit of strategy genetic testing is 16 QALYs. The incremental net monetary benefit of strategic genetic testing versus no genetic testing is US$ 88,893. Genetic testing is the strategy with the highest expected net benefit. The outcomes derived from our primary analysis remained robust when subjected to variations in all underlying assumptions and parameter values.

Conclusion

Genetic testing of Arg16Gly ADRB2 is a cost‐effective strategy to address asthma management in asthmatic children requiring ICS+LABA. This result should encourage the generation of more evidence and the incorporation of such evidence into clinical practice guidelines for pediatric asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaCost-Benefit AnalysisReceptors, Adrenergic, beta-2Adrenergic beta-2 Receptor AgonistsAdrenal Cortex HormonesGenotypeQuality-Adjusted Life YearsHumansAdministration, InhalationChildColombiaAnti-Asthmatic AgentsFemaleMaleAdolescentGenetic TestingCost-Effectiveness Analysis

Stichwörter der Autor:innen

Markov modelasthmacost‐utility analysisgenotype

Substanzen

Receptors, Adrenergic, beta-2Adrenergic beta-2 Receptor AgonistsAdrenal Cortex HormonesADRB2 protein, humanAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Research Group in Pharmacology and Toxicology, Department of Pharmacology and Toxicology, University of Antioquia, Medellín, Colombia.
  • Warwick Evidence, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
  • Laboratorio Integrado de Medicina Especializada (LIME), Facultad de Medicina, IPS Universitaria, Universidad de Antioquia, Antioquia, Colombia.

ORCID-Profile: Jefferson Antonio Buendía, Andrés Felipe Zuluaga Salazar

Förderung

  • This study was supported by the funding of authors

Zitieren

APA

Buendía, J. A., & Salazar, A. F. Z. (2024). Genotype‐driven asthma prescribing of inhaled corticosteroids and long‐acting β2‐agonist: A cost‐effectiveness analysis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27037

Vancouver

Buendía JA, Salazar AFZ. Genotype‐driven asthma prescribing of inhaled corticosteroids and long‐acting β2‐agonist: A cost‐effectiveness analysis. Pediatric Pulmonology. 2024. doi:10.1002/ppul.27037

BibTeX
@article{Buenda2024,
  author = {Buendía, Jefferson Antonio and Salazar, Andrés Felipe Zuluaga},
  title = {Genotype‐driven asthma prescribing of inhaled corticosteroids and long‐acting β2‐agonist: A cost‐effectiveness analysis},
  journal = {Pediatric Pulmonology},
  year = {2024},
  doi = {10.1002/ppul.27037}
}
Kostenlos starten →